The deal is Merck’s largest since 2015, when it spent $17bn on acquiring Sigma-Aldrich, also a life sciences specialist.
Germany’s Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota ...
A German company that provides products and services that accelerate drug development and manufacturing is set to acquire the ...
Merck KGaA has agreed to acquire Bio-Techne (NasdaqGS:TECH) for $11.5b in an all cash deal. Bio-Techne's board has ...
By Christy Santhosh, Padmanabhan Ananthan and Bhanvi Satija June 25 (Reuters) - German drugmaker Merck KGaA said on Thursday ...
Bio-Techne Corp, has agreed to an acquisition offer by Germany’s Merck KGaA for about $11.3 billion, the largest M&A deal ...
Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation, a Minneapolis-based ...
Merck’s $11.3B Bio‑Techne deal spotlights life sciences tools stocks. Check top 10 quant-rated healthcare stocks ...
The transaction is a big splash for Merck KGaA, representing the company’s largest deal since its buyout of Sigma-Aldrich for ...
Activist investor Ananym Capital Management has built a stake in Bio-Techne Corp. and is pushing the board to conduct a strategic review that would include a potential sale.
Bio-Techne rallied for a third straight day on Thursday, surging 20.08 percent to close at $70.70 apiece, as investors ...
Q1 beat and Bio-Techne deal drive upside, but valuation looks full. Read here for a detailed investment analysis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results